Asia-Pacific metabolic disorder therapeutics market is estimated to grow at a CAGR of 8.2% during the forecast period. Obesity and Diabetes is a major health concern in the countries including China and India. As per the World Health Organization (WHO), obesity rates in younger children in China (ages 5-19) was 17.5% in 2016. 1 in 5 Chinese children is obese or overweight, increased from just 1 in 20 in 1995. Further, as per the World Bank, in China, the prevalence of diabetes among the population ages 20-79 was 9.2% in 2019. This results in an increasing demand for insulin-sensitizing drugs, including thiazolidinediones and metformin, for the treatment of any type 2 diabetic patient.
These drugs can also be used in patients suffering from metabolic syndrome. At the starting of the therapy, metformin is normally used and thereafter insulin sensitizers (PPAR-gamma stimulators) including rosiglitazone are also recommended. PPARgamma (peroxisome- proliferator-activated receptor-gamma) is considered as a crucial therapeutic target to treat diabetes which arises from its effects of hypoglycemic in diabetic patients and also plays a critical role in controlling CVD functions.
To Request a Sample of our Report on Asia-Pacific Metabolic Disorder Therapeutics Market: https://www.omrglobal.com/request-sample/asia-pacific-metabolic-disorder-therapeutics-market
Scope of the Asia-Pacific Metabolic Disorder Therapeutics Market
Market Coverage
- Market number available for 2021-2030
- Base year- 2021
- Forecast period- 2023-2030
- Segment Covered- By Therapy and Disease
- Countries Covered- China, India, Japan, and Rest of Asia-Pacific
- Competitive Landscape- Lupin Ltd., Shanghai Fosun Pharmaceutical Group (Co.) Ltd., AstraZeneca plc, and Cipla Inc.
Asia-Pacific Metabolic Disorder Therapeutics Market-Segmentation
By Therapy
- Drug Therapy
- Gene Therapy
- Cellular Transplantation
- Enzyme Replacement Therapy
- Others
By Disease
- Obesity
- Diabetes
- Lysosomal Storage Disease
- Hypercholesterolemia
- Others
A full Report of Asia-Pacific Metabolic Disorder Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-metabolic-disorder-therapeutics-market
Asia-Pacific Metabolic Disorder Therapeutics Market– Segment by Country
- China
- Japan
- India
Rest of Asia-Pacific
Company Profiles
- Astellas Pharma, Inc.
- Biocon, Ltd.
- Cipla, Inc.
- Dr. Reddy's Laboratories, Ltd.
- Hengrui Therapeutics, Inc.
- Lupin, Ltd.
- Shanghai Fosun Pharmaceutical Group (Co.), Ltd.
- Shanghai Pharmaceuticals Holding Co., Ltd.
- Sun Pharmaceutical Industries, Ltd.
- Takeda Pharmaceutical Co., Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-metabolic-disorder-therapeutics-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404